Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis

Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis

Background. Based on PACIFIC trial, durvalumab as consolidation therapy following concurrent chemoradiotherapy (cCRT) has been a new standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). In clinical applications, there are heterogeneous adjustments or novel strategies fol...

Full description

Saved in:

Bibliographic Details
Main Authors:	Luqing Zhao, Zhiting Zhao, Xiaoqi Yan, Fei Wu, Ning Sun, Renhong Guo, Shaorong Yu, Xiao Hu, Jifeng Feng
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	International Journal of Clinical Practice
Online Access:	http://dx.doi.org/10.1155/2024/8585035
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Partial Stereotactic Ablative Radiotherapy Boost Before Conventional Radiotherapy (P‐SABR) for Large (> 5 cm) Unresectable Stage III Nonsmall Cell Lung Cancer
by: Yun Bai, et al.
Published: (2025-01-01)

Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases
by: Yaqing Kong, et al.
Published: (2025-12-01)

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
by: Mauro Zukin, et al.
Published: (2025-01-01)

Surgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching
by: Takao Shigenobu, et al.
Published: (2025-01-01)

Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer
by: Jinbo Ma MD, et al.
Published: (2025-01-01)

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy
by: Hohyung Nam, et al.
Published: (2025-01-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01)

The effect of the relative dose intensity of chemoradiotherapy on the effectiveness of therapy of locally advanced unresectable non-small cell lung cancer
by: A. E. Glukhareva, et al.
Published: (2024-03-01)

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)

Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study
by: Yi Peng MD, et al.
Published: (2025-01-01)

Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma
by: Zhaosong Xue, et al.
Published: (2025-02-01)

Association of tumour mutation burden with prognosis and its clinical significance in stage III gastric cancer
by: Ya-Lin Han, et al.
Published: (2024-11-01)

Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab
by: Ashish Gupta, et al.
Published: (2019-01-01)

Comparison of fluorescence in situ hybridization (FISH) and urine cytology in diagnosing urothelial carcinoma: a single-center retrospective cohort study
by: WANG Zhiting, et al.
Published: (2024-12-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer
by: Zhiwei Chen, et al.
Published: (2025-01-01)

Mediastinal Staging for Lung Cancer
by: Jacob Gelberg, et al.
Published: (2014-01-01)

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Progress of diagnosis and treatment decisions in stage Ⅲ/Ⅳ periodontitis
by: CHEN Xu, LI Lu, WANG Xiaoqian, WANG Tianyao, XU Yan
Published: (2025-01-01)

Rare Lung Diseases III: Pulmonary Langerhans’ Cell Histiocytosis
by: Stephen C Juvet, et al.
Published: (2010-01-01)

Clinical calculator based on clinicopathological characteristics predicts local recurrence and overall survival following radical resection of stage II-III colorectal cancer
by: Fei Huang, et al.
Published: (2025-02-01)

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
by: Hidekazu Hirano, et al.
Published: (2025-02-01)

Class III Orthodontic Camouflage: Is the “Ideal” Treatment Always the Best Option? A Documented Case Report
by: Lorenzo Rustico, et al.
Published: (2022-01-01)

Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
by: Linfeng Wang, et al.
Published: (2025-01-01)

Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
by: Liu Song, et al.
Published: (2025-01-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
by: Ji Eun Shin, et al.
Published: (2025-02-01)

MOLAR INCISOR HYPOMINERALIZATION (MIH) – THERAPEUTIC OPTIONS FOR THE FIRST PERMANENT MOLARS
by: Olimpia Bunta, et al.
Published: (2024-12-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma
by: Ricarda Seidensticker, et al.
Published: (2016-01-01)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
by: Hiroyuki Iwasaki, et al.
Published: (2020-01-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Lie Symmetry Analysis of a First-Order Feedback Model of Option Pricing
by: Winter Sinkala, et al.
Published: (2015-01-01)

Role of CT in Assessment of Unresectable Wilms' Tumor Response after Preoperative Chemotherapy in Pediatrics
by: Huda Refaie, et al.
Published: (2008-01-01)

Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy
by: Robert M. Samstein, et al.
Published: (2014-01-01)